ArticleContemporary clinical trials communications2019

Efficacy and safety of cytokines versus first-line sunitinib and second-line axitinib for patients with metastatic renal cell carcinoma (ESCAPE study): A study protocol for phase III randomized sequential open-label study.

Yoshifumi Kadono et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.